Blood cancers

PBS listings approved for haematological cancer drugs and biosimilars

Patients with mantle cell lymphoma may soon gain access to ibrutinib (Imbruvica) on the PBS. At its March 2018 meeting the Pharmaceutical Benefits Advisory Committee (PBAC) recommended expansion of the PBS listing for the immune therapy to include patients with relapsed/refractory mantle cell lymphoma (MCL). The PBAC said its recommendation for MCL “reflected the high ...

Already a member?

Login to keep reading.

© 2021 the limbic